Lincoln Pharmaceuticals (531633) Stock Overview
Engages in manufacturing and trading of pharmaceutical products in India. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
No risks detected for 531633 from our risk checks.
531633 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Lincoln Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹550.05 |
| 52 Week High | ₹975.00 |
| 52 Week Low | ₹500.00 |
| Beta | 0.31 |
| 1 Month Change | -6.05% |
| 3 Month Change | -0.38% |
| 1 Year Change | -15.07% |
| 3 Year Change | 77.01% |
| 5 Year Change | 194.38% |
| Change since IPO | 2,191.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| 531633 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -2.1% | -0.4% | -1.0% |
| 1Y | -15.1% | 9.1% | -2.8% |
Return vs Industry: 531633 underperformed the Indian Pharmaceuticals industry which returned 9.1% over the past year.
Return vs Market: 531633 underperformed the Indian Market which returned -2.8% over the past year.
Price Volatility
| 531633 volatility | |
|---|---|
| 531633 Average Weekly Movement | 4.1% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in IN Market | 8.4% |
| 10% least volatile stocks in IN Market | 3.9% |
Stable Share Price: 531633 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 531633's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1979 | 1,687 | Mahendrabhai Patel | www.lincolnpharma.com |
Lincoln Pharmaceuticals Limited engages in manufacturing and trading of pharmaceutical products in India. The company offers products in the areas of anticold, antibiotic, otolaryngology, pain management, gastro, anti-malarial, anti-fungal, corticosteroids and cosmo-derma, anti-diabetic, anti-hypertensive, gynecology, cardio and CNS, respiratory system, and dyslipidemic; and branded generics. It also exports its products to approximately 60 countries, including Europe, Canada, Latin and North America, Africa, the Asia Pacific, and South East Asia.
Lincoln Pharmaceuticals Limited Fundamentals Summary
| 531633 fundamental statistics | |
|---|---|
| Market cap | ₹11.02b |
| Earnings (TTM) | ₹823.46m |
| Revenue (TTM) | ₹6.23b |
Is 531633 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 531633 income statement (TTM) | |
|---|---|
| Revenue | ₹6.23b |
| Cost of Revenue | ₹2.91b |
| Gross Profit | ₹3.32b |
| Other Expenses | ₹2.50b |
| Earnings | ₹823.46m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 41.11 |
| Gross Margin | 53.26% |
| Net Profit Margin | 13.21% |
| Debt/Equity Ratio | 0% |
How did 531633 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/13 18:10 |
| End of Day Share Price | 2025/07/11 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lincoln Pharmaceuticals Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kameswari V. S. Chavali | FirstCall Research |